Read More

Black Diamond Therapeutics Highlights Presentation Of Preclinical Data On BDTX-1535, B-Raf, Fibroblast Growth Factor Receptor Programs At AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the presentation of preclinical data for three

BDTX